SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the introduction of a modular set of high-parameter Maxpar® mass cytometry panels for immuno-oncology research. Designed for use with Helios™ and CyTOF® systems, the Immuno-Oncology Maxpar Panels enable researchers to simultaneously profile T cell subpopulations across 34 highly informative markers to comprehensively identify all major T cell subsets, measure checkpoint molecule expression, identify activation states and determine homing status. Provided as a modular panel system, these panels can be easily combined for complete coverage. Individual panel sets can also be further customized with additional markers for specific research needs. With access to over 600 commercially available pre-conjugated antibodies and custom conjugation options from Fluidigm, this panel system is very well suited to meet the evolving needs of the cancer immunotherapy research community. "The dynamic nature and inherent complexity of the anti-tumor immune response requires new approaches to deeply profile cell populations at single-cell resolution," said Chris Linthwaite, President and CEO of Fluidigm. "This new set of multi-parameter panels will empower more researchers with high-dimensional tools to interrogate the tumor immune response and the tumor microenvironment, maximizing the information obtained from each precious sample." Mass cytometry is fast becoming an industry standard for deep cellular profiling in translational and clinical research. Referenced by hundreds of peer-reviewed publications around the world, mass cytometry uniquely expands beyond the inherent technical limitations of flow cytometry. With little to no spectral overlap, researchers can interrogate over 40 parameters simultaneously from millions of cells across both intracellular and extracellular protein markers. "Enabling the immune system to recognize and eliminate tumors has tremendous potential to change the way cancer is treated and eventually cured," continued Chris Linthwaite. "Using the unique power of mass cytometry, the immuno-oncology research community can identify new biomarkers and optimize the development of new cancer immunotherapies to fully realize the potential of this transformative approach to cancer care."